In Silico Simulation of Aptamer-Tau Interactions for Alzheimer's Disease Therapy
JSHS · 2025
Overview
Alzheimer's disease (AD) is the leading cause of dementia, characterized by the pathological accumulation of amyloid -beta (Aβ) plaques and tau protein aggregates, which disrupt neuronal signaling and lead to cognitive decline. In recent years, aptamers —short, structured oligonucleotides with high affinity and specificity for target biomolecules —have emerged as promising therapeutic agents for neurodegenerative diseases. Recently, bi -specific DNA-based aptamers, which first pass the BBB via transferrin recep tors and later inhibit tau oligomerization, have been developed. I hypothesize that tau proteins contain specific binding sites that enable aptamer interaction, thereby preventing fibril formation. This study focuses on the computational characterization of bi-specific aptamers that facilitate blood -brain barrier (BBB) penetration via transferrin receptors and subsequently inhibit tau oligomerization. The three -dimensional structures of aptamers were generated using the Vfold, incorporating both secondary and tertiary structures. Molecular docking simulations were conducted using HDOCK to analyze aptamer interactions with transferrin receptors and tau proteins. P2Rank further validated the docking results for binding site prediction and electrostatic surface potential (ESP) analysis to assess complementarity and molecular interactions. Lastly, molecular docking results were analyzed using virtual reality (VR) technology. Among the aptamers tested, BW1c exhibited a strong binding affinity to tau protein, suggesting its potential as a first-in-class aptamer-based therapeutic for AD. In addition to computational simulations, I have also designed a novel aptamer analysis pipeline (APTASCAN) that can be used to facilitate future aptamer research. These findings provide a computational framework for designing novel aptamer -based interventions for neurodegenerative disorders.
Competition history
- JSHS 2025
Resources
Related projects
ISEF · 2024
Selection and Preclinical Testing of DNA Aptamers as Targeted Tau Therapies: A Novel Approach to Slow the Progression of Tauopathies
ISEF · 2022
In silico High-Throughput Identification of Novel Dual Amyloid Beta and Tau Aggregation Inhibitors for Alzheimer's Disease Treatments
ISEF · 2025
A Novel Genomic Framework for Personalized Medicine: Optimizing LMTX for Tau Proteins in Alzheimer's
JSHS · 2025
AI-Mediated Computational Analysis of Bispecific RNA-Based Aptamers Targeting the Transferrin Receptor of Blood Brain Barrier and EpCAM in Glioblastoma
JSHS · 2025
AI-Mediated Computational Analysis of RNA-Based Aptamers Targeting the CD133+ Glioblastoma Cells
ISEF · 2026
Designing Peptide Inhibitors to Prevent Amyloid Beta Aggregation
ISEF · 2024
Targeting Amyloid-ß Plaques: In silico Protein Modeling of Novel Antibody for Halting Alzheimer's Disease Progression
ISEF · 2020
Mining Common Structural Features of Aggregating Proteins in Neurodegenerative Diseases
Closest projects by meaning, across every fair and year in the corpus.